TrialCancer medicine2023

Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Kaiyan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.